Sigmoid Pharma | Developing products with LEDDS® and SmPill® technologies

By: Sigmoid Pharma  05/12/2011
Keywords: Drug Absorption, Hydrophobic Peptide Drug

Sigmoid is developing a number of products of its own, each incorporating the Company’s LEDDS® and SmPill® technologies. The three most advanced projects are novel formulations being developed for indications in gastro-intestinal disease, transplantation and neuro-degeneration.

In establishing its in-house pipeline of development stage products, Sigmoid is drawing on positive clinical proof-of-concept studies conducted with a marketed hydrophobic peptide drug. These studies demonstrate very significantly enhanced and accelerated drug absorption and have provided the basis for expanding the company’s activities.

Note: This page is being updated.  Please visit again soon

Keywords: Drug Absorption, Hydrophobic Peptide Drug

Contact Sigmoid Pharma

Email - none provided

Print this page